The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Open accessAbstract
Remdesivir (GS-5734) is a 1′-cyano-substituted adenosine nucleotide analogue prodrug that shows broad-spectrum antiviral activity against several RNA viruses. This compound is currently under clinical development for the treatment of Ebola virus disease (EVD). While antiviral effects have been demonstrated in cell culture and in non-human primates, the mechanism of action of Ebola virus (EBOV) inhibition for remdesivir remains to be fully elucidated. The EBOV RNA-dependent RNA polymerase (RdRp) complex was recently expressed and purified, enabling biochemical studies with the relevant triphosphate (TP) form of remdesivir and its presumptive target. In this study, we confirmed that remdesivir-TP is able to compete for incorporation with adenosine triphosphate (ATP). Enzyme kinetics revealed that EBOV RdRp and respiratory syncytial virus (RSV) RdRp incorporate ATP and remdesivir-TP with similar efficiencies. The selectivity of ATP against remdesivir-TP is ~4 for EBOV RdRp and ~3 for RSV RdRp. In contrast, purified human mitochondrial RNA polymerase (h-mtRNAP) effectively discriminates against remdesivir-TP with a selectivity value of ~500-fold. For EBOV RdRp, the incorporated inhibitor at position i does not affect the ensuing nucleotide incorporation event at position i+1. For RSV RdRp, we measured a ~6-fold inhibition at position i+1 although RNA synthesis was not terminated. Chain termination was in both cases delayed and was seen predominantly at position i+5. This pattern is specific to remdesivir-TP and its 1′-cyano modification. Compounds with modifications at the 2′-position show different patterns of inhibition. While 2′-C-methyl-ATP is not incorporated, ara-ATP acts as a non-obligate chain terminator and prevents nucleotide incorporation at position i+1. Taken together, our biochemical data indicate that the major contribution to EBOV RNA synthesis inhibition by remdesivir can be ascribed to delayed chain termination. The long distance of five residues between the incorporated nucleotide analogue and its inhibitory effect warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Self-citationAgostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
Self-citationFavipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. (2014) · Nature · doi:10.1038/nature13777 · Cited by 987
Broad-Spectrum Antiviral Activity of Virazole: 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
Sidwell, R. W., Huffman, J. H., Khare, L., Allen, B., Witkowski, R., & Robins, K. (1972) · Science · doi:10.1126/science.177.4050.705 · Cited by 985
Henao-Restrepo, A. M., Longini, I. M., Egger, M., Dean, N. E., Edmunds, W. J., Camacho, A., Carroll, M. W., Doumbia, M., Draguez, B., Duraffour, S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61117-5 · Cited by 793
Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., Neville, S., Carra, E., Lew, W., Ross, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01594 · Cited by 643
Self-citationProtection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Warren, T. K., Wells, J., Panchal, R. G., Stuthman, K. S., Garza, N. L., Van Tongeren, S. A., Dong, L., Retterer, C. J., Eaton, B. P., Pegoraro, G., et al. (2014) · Nature · doi:10.1038/nature13027 · Cited by 610
Cited by
Guo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Self-citationStructural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. (2020) · Science · doi:10.1126/science.abc1560 · Cited by 1,219
“Thus, Remdesivir, like many nucleotide analog prodrugs, inhibits the viral RdRp activity through non-obli-gate RNA chain termination, a mechanism that requires the conversion of the parent drug to the active triphosphate form ( 27 , 28 ).”
BackgroundSheahan, T. P., Sims, A. C., Zhou, S., Graham, R. L., Pruijssers, A. J., Agostini, M. L., Leist, S. R., Schäfer, A., Dinnon, K. H., Stevens, L. J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5883 · Cited by 1,071
The epidemiology, diagnosis and treatment of COVID-19
Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y., & Li, Y. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105955 · Cited by 1,014
Gordon, C. J., Tchesnokov, E. P., Woolner, E., Perry, J. K., Feng, J. Y., Porter, D. P., & Götte, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013679 · Cited by 985
Self-citationEastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A., Shen, M., Patnaik, S., & Hall, M. D. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00489 · Cited by 953
Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ac120.013056 · Cited by 850
Self-citationStructure of replicating SARS-CoV-2 polymerase
Hillen, H. S., Kokic, G., Farnung, L., Dienemann, C., Tegunov, D., & Cramer, P. (2020) · Nature · doi:10.1038/s41586-020-2368-8 · Cited by 790
Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase
Wang, Q., Wu, J., Wang, H., Gao, Y., Liu, Q., Mu, A., Ji, W., Yan, L., Zhu, Y., Zhu, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.034 · Cited by 776
COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment
Parasher, A. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138577 · Cited by 776
COVID-19: Immunology and treatment options
Felsenstein, S., Herbert, J. A., McNamara, P. S., & Hedrich, C. M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108448 · Cited by 669
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
Kokic, G., Hillen, H. S., Tegunov, D., Dienemann, C., Seitz, F., Schmitzova, J., Farnung, L., Siewert, A., Höbartner, C., & Cramer, P. (2021) · Nature Communications · doi:10.1038/s41467-020-20542-0 · Cited by 603
Candidate drugs against SARS-CoV-2 and COVID-19
McKee, D. L., Sternberg, A., Stange, U., Laufer, S., & Naujokat, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104859 · Cited by 562
Romano, M., Ruggiero, A., Squeglia, F., Maga, G., & Berisio, R. (2020) · Cells · doi:10.3390/cells9051267 · Cited by 527
Brown, A. J., Won, J. J., Graham, R. L., Dinnon, K. H., Sims, A. C., Feng, J. Y., Cihlar, T., Denison, M. R., Baric, R. S., & Sheahan, T. P. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104541 · Cited by 510
Self-citationA Guide to COVID‐19: a global pandemic caused by the novel coronavirus SARS‐CoV‐2
Atzrodt, C. L., Maknojia, I., McCarthy, R. D. P., Oldfield, T. M., Po, J., Ta, K. T. L., Stepp, H. E., & Clements, T. P. (2020) · The FEBS Journal · doi:10.1111/febs.15375 · Cited by 341
Arguments in favour of remdesivir for treating SARS-CoV-2 infections
Ko, W.-C., Rolain, J.-M., Lee, N.-Y., Chen, P.-L., Huang, C.-T., Lee, P.-I., & Hsueh, P.-R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105933 · Cited by 316
Hall, D. C., & Ji, H.-F. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101646 · Cited by 296
The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase
Lung, J., Lin, Y., Yang, Y., Chou, Y., Shu, L., Cheng, Y., Liu, H. T., & Wu, C. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25761 · Cited by 295
Remdesivir against COVID-19 and Other Viral Diseases
Malin, J. J., Suárez, I., Priesner, V., Fätkenheuer, G., & Rybniker, J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00162-20 · Cited by 295
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
Gordon, C. J., Tchesnokov, E. P., Schinazi, R. F., & Götte, M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100770 · Cited by 293
Self-citationStructural biology of SARS-CoV-2: open the door for novel therapies
Yan, W., Zheng, Y., Zeng, X., He, B., & Cheng, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00884-5 · Cited by 291
Alanagreh, L., Alzoughool, F., & Atoum, M. (2020) · Pathogens · doi:10.3390/pathogens9050331 · Cited by 291
Lamb, Y. N. (2020) · Drugs · doi:10.1007/s40265-020-01378-w · Cited by 284
Current epidemiological and clinical features of COVID-19; a global perspective from China
Tu, H., Tu, S., Gao, S., Shao, A., & Sheng, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.011 · Cited by 283
COVID-19: Characteristics and Therapeutics
Chilamakuri, R., & Agarwal, S. (2021) · Cells · doi:10.3390/cells10020206 · Cited by 282
COVID-19: A review of therapeutic strategies and vaccine candidates
Izda, V., Jeffries, M. A., & Sawalha, A. H. (2021) · Clinical Immunology · doi:10.1016/j.clim.2020.108634 · Cited by 274
Current Status of COVID-19 Therapies and Drug Repositioning Applications
Altay, O., Mohammadi, E., Lam, S., Turkez, H., Boren, J., Nielsen, J., Uhlen, M., & Mardinoglu, A. (2020) · iScience · doi:10.1016/j.isci.2020.101303 · Cited by 98
Zhang, L., Zhang, D., Wang, X., Yuan, C., Li, Y., Jia, X., Gao, X., Yen, H.-L., Cheung, P. P.-H., & Huang, X. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d0cp05948j · Cited by 52
COVID-19 Treatment: The Race Against Time
Aljofan, M., & Gaipov, A. (2020) · Electronic Journal of General Medicine · doi:10.29333/ejgm/7890 · Cited by 27
Koulgi, S., Jani, V., V N, M. U., Sonavane, U., & Joshi, R. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1894985 · Cited by 12
Koulgi, S., Jani, V., Uppuladinne V N, M., Sonavane, U., & Joshi, R. (2020) · doi:10.26434/chemrxiv.12886856
Metadata
- Authors
- Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2019-04-04
- Volume
- 11
- Issue
- 4
- Pages
- 326
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W2935101654
- Cited by
- 622
- References
- 44
- FWCI
- 84.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.